A patient with relapsed or refractory multiple myeloma has previously received at least one line of therapy. You are considering evidence from a phase 3 trial comparing talquetamab-containing regimens with daratumumab plus pomalidomide and dexamethasone.
What does the evidence in this abstract support for such patients?
